Hypothesis: Simple crossover strategy would be non-inferior to SB opening strategy in the risk of target lesion failure (TLF) in patients with angiographically compromised SB (visually SB stenosis ≥50%) after provisional MV stenting for non-left main bifurcation lesion. A total of 1000 patients (500 per each group) with the angiographically compromised SB (visually SB stenosis ≥50%) after provisional MV stenting for non-left main bifurcation lesion will be enrolled. Patients will be randomized to either the simple crossover strategy group or SB opening strategy group at the time of enrollment with 1:1 ratio. Stratified randomization according to participating center, clinical presentation (acute coronary syndrome or stable ischemic heart disease), and type of bifurcation lesions (true or non-true) will be performed.
Despite advances in stenting techniques and devices, percutaneous coronary intervention (PCI) for bifurcation lesions remains one of the most challenging and complex procedures. Current guidelines recommend 1-stenting with provisional side branch (SB) approach should be an initial treatment strategy for the bifurcation lesions, based on the previous results of several randomized trials. However, the standardization of the provisional strategy is limited. In particular, there is a recommendation on the treatment technique for SB when SB intervention is required, but It has not been decided in which cases SB treatment is necessary, in the latest European Bifurcation Club (EBC) consensus document.16 In previous studies, the criteria for performing SB opening after MV stent intervention in the 1-stenting with provisional SB approach were varied. In the DK-CUSH II (Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) or CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) trials, SB intervention was performed when the SB diameter stenosis more than 50%, grade B or higher dissection, or blood flow disturbance (TIMI flow 2 or less) after MV stent insertion. On the other hand, in the Nordic trial, the authors applied strict criteria for SB intervention after MV stent insertion (TIMI flow 2 or less only). Furthermore, there have been conflicting results regarding the clinical and angiographic outcomes of the jailed SB opening strategy after the main vessel (MV) stenting, compared with the simple crossover strategy for non-left main bifurcation lesion. On this background, this trial aims to compare the clinical outcomes between simple crossover and side branch opening strategies in patients with the angiographically compromised SB (visually SB stenosis ≥50%) after provisional MV stenting for non-left main bifurcation lesion.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,000
Regardless of allocated arms, stent implantation in the MV (selected 1:1 according to the distal MV size) followed by systematic proximal optimization technique (POT, post-dilatation of the stent at the level of proximal MV with a balloon diameter sized 1:1 according to the proximal MV) or POT like procedure is strongly recommended.
According to the latest European Bifurcation Club (EBC) consensus document, distal SB rewiring followed by kissing balloon inflation (eventually conducted with short non-compliant balloons) and repeat POT procedures are highly recommended. An additional stent will be allowed if major dissection or decreased TIMI flow of SB occurs during SB treatment.
Target-lesion failure
a composite of cardiac death, myocardial infarction, and target-lesion revascularization
Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)
All-cause death
Death from any causes
Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)
Cardiac death
Death from cardiac causes
Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)
Myocardial infarction
any myocardial infarction
Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)
Target-vessel myocardial infarction
myocardial infarction in target-vessel
Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)
Target-lesion revascularization
Clinically indicated target-lesion revascularization
Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)
Target-vessel revascularization
Clinically indicated target-vessel revascularization
Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)
Any revascularization
Repeat revascularization procedure
Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)
Stent thrombosis
definite or probable stent thrombosis by Academic Research Consortium \[ARC\] definition
Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)
Bleeding
Bleeding ARC type 2, 3 or 5 bleeding
Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)
Total procedure time
procedure time
Time frame: at 1 day
Total amount of contrast use
used contrast amount
Time frame: at 1 day
Incidence of contrast induced nephropathy
defined as an increase in creatinine of ≥0.5mg/dL or ≥25% from baseline within 72 hours after contrast exposure
Time frame: 72 hours after the index procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.